



3 Color CD3 FITC-CD19 RPE-CD45 RPE-Cy5+

- Product** Exalpa's 3 color system, CD3 FITC-CD19 RPE-CD45 RPE-Cy5. Single laser excitation at 488 nm. All 3 color reagents are pre-titered and pre-tested for optimal performance.
- Description** Use Exalpa's 3 color CD markers to add flexibility to your current single laser system capabilities.
- The CD3 epitope is expressed on the epsilon chain of the CD3/T cell antigen receptor (TcR) complex. CD3 is present on 65-85% of thymocytes and has a mitogenic effect on peripheral blood T cells. CD3 identifies human T cells expressing the 22-28,000 M.W surface antigen. CD19 identifies human B cells associated with 10% of peripheral blood lymphocytes. CD19 identifies lymphocytes expressing the 95,000 M.W. surface antigen. CD45 identifies all human leucocytes, lymphocytes, monocytes, polymorphonuclear cells, eosinphils and basophils in peripheral blood expressing the 180-220K M.W. T200 family surface antigen. CD45 is also present on thymus,spleen, tonsil and progenitor cells in bone marrow.
- Isotype** Mouse IgG1 kappa /IgG1 kappa/IgG1 kappa.
- Clone** M2AB (CD3 FITC)/1G9 (CD19 RPE)/ BHPT-6 (CD45 RPE-Cy5)
- Fluorescence Information** RPE-Cy5 is compatible with 488 nm single argon laser applications. With absorbence at 488nm and emission at 667 nm it is ideally suited for multi-color analysis on single laser instruments.
- | <u>Dye</u> | <u>Excitation</u> | <u>Emission</u> |
|------------|-------------------|-----------------|
| FITC | 488 nm | 530 EM max nm |
| RPE | 488 nm | 565 EM max nm |
| RPE-Cy5 | 488 nm | 667 EM max nm |
- Applications** When using Exalpa's 3 color system CD3/19/45 it is appropriate to gate on CD45 RPE-Cy5 cell populations. Subsequent analysis may be done on the CD3 FITC and CD19 RPE cell populations.
Monitoring of T cells subsets in peripheral blood.
Characterization of subtypes of T cell leukemia's and lymphomas.
Studies of AIDS/HIV virus infection.
Analysis of CD3 complex related to the T cell antigen receptor.
Monitoring of B cells in peripheral blood.
Analysis of B cell subsets.
Study of B cell activation.
Study of B cell neoplasms.
Monitoring of Leukocyte cells subsets in peripheral blood.
Studies of progenitor cells in bone marrow.
- Use** PBMC: Add 10 µl of Exalpa's 3 color antibody reagent/10⁶ PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2° to 8° C. Wash twice with PBS or fix with 0.5% v/v of paraformaldehyde in PBS and analyze.

For research use only. Not for use in human diagnostics or therapeutics.

WHOLE BLOOD: Add 10 µl of Exalpa's 3 color antibody reagent MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20° C. Lyse the whole blood. Wash once with PBS or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Storage Exalpa's 3 color reagents are supplied in PBS, 0.08% sodium azide and 0.2% carrier protein. Our conjugated monoclonal antibodies should be stored at 4 - 8° C until use. Exalpa's conjugated monoclonal antibodies should never be frozen. When stored properly they are stable for the period shown on the vial label.

Ordering Information	3 Color Form	Vial Size	Catalog#
	CD3/19/45	200 Test	X1066
	CD3/19/45	50 Test	X1066s

+ Portions of this product are manufactured under license from Carnegie Mellon University, U.S. Patent no. 5268486

For research use only. Not for use in human diagnostics or therapeutics.

WARNING: Reagents containing sodium azide under acid conditions yields hydrazoic acid, an extremely toxic compound. Azide containing compounds should be discarded with proper caution. There are no warranties, expressed or implied, which extend beyond the description on the label of the product. Exalpa is not liable for property damage, personal injury or economic loss caused by the product. Nothing disclosed herein is to be construed as a recommendation to use Exalpa's products in violation of any patents. Exalpa cannot be responsible for patent infringement or other violations that may occur by the use of its products.